TY - JOUR
T1 - Emerging topics and practical aspects for an appropriate use of amyloid PET in the current Italian context
AU - Nobili, Flavio
AU - Cagnin, Annachiara
AU - Calcagni, Maria Lucia
AU - Chincarini, Andrea
AU - Guerra, Ugo P.
AU - Morbelli, Silvia
AU - Padovani, Alessandro
AU - Paghera, Barbara
AU - Pappatà, Sabina
AU - Parnetti, Lucilla
AU - Sestini, Stelvio
AU - Schillaci, Orazio
PY - 2019
Y1 - 2019
N2 - In May 2017 some representatives of the Italian nuclear medicine and neurological communities spontaneously met to discuss the issues emerged during the first two years of routine application of amyloid PET with fluorinated radiopharmaceuticals in the real world. The limitations of a binary classification of scans, the possibility to obtain early images as a surrogate marker of regional cerebral bloos flow, the need for (semi-)quantification and, thus, the opportunity of ranking brain amyloidosis, the correlation with Aβ42 levels in the cerebrospinal fluid, the occurrence and biological meaning of uncertain/boderline scans, the issue of incidental amyloidosis, the technical pittfalls leading to false negative/positive results, the position of the tool in the diagnostic flow-chart in the national reality, are the main topics that have been discussed. Also, a card to justify the examination to be filled by the dementia specialist and a card for the nuclear medicine physician to report the exam in detail have been approved and are available in the web, which should facilitate the creation of a national register, as previewed by the 2015 intersocietal recom-mendation on the use of amyloid PET in Italy. The content of this discussion could stimulate both public institutions and companies to support further research on these topics.
AB - In May 2017 some representatives of the Italian nuclear medicine and neurological communities spontaneously met to discuss the issues emerged during the first two years of routine application of amyloid PET with fluorinated radiopharmaceuticals in the real world. The limitations of a binary classification of scans, the possibility to obtain early images as a surrogate marker of regional cerebral bloos flow, the need for (semi-)quantification and, thus, the opportunity of ranking brain amyloidosis, the correlation with Aβ42 levels in the cerebrospinal fluid, the occurrence and biological meaning of uncertain/boderline scans, the issue of incidental amyloidosis, the technical pittfalls leading to false negative/positive results, the position of the tool in the diagnostic flow-chart in the national reality, are the main topics that have been discussed. Also, a card to justify the examination to be filled by the dementia specialist and a card for the nuclear medicine physician to report the exam in detail have been approved and are available in the web, which should facilitate the creation of a national register, as previewed by the 2015 intersocietal recom-mendation on the use of amyloid PET in Italy. The content of this discussion could stimulate both public institutions and companies to support further research on these topics.
KW - Alzheimer disease
KW - Amyloid
KW - Amyloidosis
KW - Brain
KW - Humans
KW - Image Processing, Computer-Assisted
KW - Italy
KW - Language
KW - Neurodegenerative diseases
KW - Positron-Emission Tomography
KW - Positron-emission tomography
KW - Radioactive Tracers
KW - Alzheimer disease
KW - Amyloid
KW - Amyloidosis
KW - Brain
KW - Humans
KW - Image Processing, Computer-Assisted
KW - Italy
KW - Language
KW - Neurodegenerative diseases
KW - Positron-Emission Tomography
KW - Positron-emission tomography
KW - Radioactive Tracers
UR - http://hdl.handle.net/10807/139732
U2 - 10.23736/S1824-4785.18.03069-8
DO - 10.23736/S1824-4785.18.03069-8
M3 - Article
SN - 1824-4785
VL - 63
SP - 83
EP - 92
JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging
JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging
ER -